Jin, Ying-Hui;
Zhan, Qing-Yuan;
Peng, Zhi-Yong;
Ren, Xue-Qun;
Yin, Xun-Tao;
Cai, Lin;
Yuan, Yu-Feng;
Yue, Ji-Rong;
Zhang, Xiao-Chun;
Yang, Qi-Wen;
Ji, Jianguang;
Xia, Jian;
Li, Yi-Rong;
Zhou, Fu-Xiang;
Gao, Ya-Dong;
Yu, Zhui;
Xu, Feng;
Tu, Ming-Li;
Tan, Li-Ming;
Yang, Min;
Chen, Fang;
Zhang, Xiao-Ju;
Zeng, Mei;
Zhu, Yu;
Liu, Xin-Can;
Yang, Jian;
Zhao, Dong-Chi;
Ding, Yu-Feng;
Hou, Ning;
Wang, Fu-Bing;
Chen, Hao;
Zhang, Yong-Gang;
Li, Wei;
Chen, Wen;
Shi, Yue-Xian;
Yang, Xiu-Zhi;
Wang, Xue-Jun;
Zhong, Yan-Jun;
Zhao, Ming-Juan;
Li, Bing-Hui;
Ma, Lin-Lu;
Zi, Hao;
Wang, Na;
Wang, Yun-Yun;
Yu, Shao-Fu;
Li, Lu-Yao;
Huang, Qiao;
Weng, Hong;
Ren, Xiang-Ying;
Luo, Li-Sha;
Fan, Man-Ru;
Huang, Di;
Xue, Hong-Yang;
Yu, Lin-Xin;
Gao, Jin-Ping;
Deng, Tong;
Zeng, Xian-Tao;
Li, Hong-Jun;
Cheng, Zhen-Shun;
Yao, Xiaomei;
Wang, Xing-Huan.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness,
coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis
and treatment guidelines for clinicians caring for patients are needed. In the ...
Chemoprevention/methods,
Coronavirus Infections/diagnosis,
Coronavirus Infections/drug therapy,
Pneumonia, Viral/diagnosis,
Pneumonia, Viral/drug therapy,
Pandemics/prevention & control,
Betacoronavirus/drug effects,
Evidence-Based Practice/methods,
Anti-Retroviral Agents/therapeutic use,
Lopinavir/therapeutic use,
Chloroquine/therapeutic use,
Receptors, Interleukin-6/therapeutic use,
Hydroxychloroquine/therapeutic use,
Plasma/immunology
Moores, Lisa K;
Tritschler, Tobias;
Brosnahan, Shari;
Carrier, Marc;
Collen, Jacob F;
Doerschug, Kevin;
Holley, Aaron B;
Jimenez, David;
Gal, Gregoire Le;
Rali, Parth;
Wells, Philip.
Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and VTE. This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of...
The purpose of this guideline is to ensure the best antibiotic management of suspected or confirmed bacterial pneumonia in adults in hospital during the COVID‑19 pandemic. This includes people presenting to hospital with moderate to severe community-acquired pneumonia and people who develop pneumonia w...
Betacoronavirus,
Pneumonia, Viral/complications,
Coronavirus Infections/complications,
Antibiotics, Antitubercular/therapeutic use,
Coronavirus Infections/drug therapy,
Pneumonia, Viral/drug therapy,
Hospitals/standards,
Coronavirus Infections/diagnosis,
Pneumonia, Viral/diagnosis
This guideline aims to provide specific, patient-focused recommendations on management and care of people with suspected or confirmed COVID-19. With the exception of chemoprophylaxis for the prevention of infection in people exposed to COVID-19, the guideline does not include other interventions used in ...
Clinical Diagnosis/diagnosis,
Betacoronavirus/drug effects,
Coronavirus Infections/diagnosis,
Pneumonia, Viral/diagnosis,
Hypoxia/diagnosis,
Patient Acuity,
Coronavirus Infections/drug therapy,
Pneumonia, Viral/drug therapy,
Dexamethasone/therapeutic use,
Breast Feeding,
Antiviral Agents/therapeutic use,
Hydroxychloroquine/therapeutic use,
Colchicine/therapeutic use,
Plasma/immunology,
Darunavir/therapeutic use,
Interferons/therapeutic use,
Evidence-Based Practice/methods